Transcript Catalysing The Growth Of An Innovation Driven Biotech

Biotechnology Industry Research Assistance Council
(A Government of India Enterprise)
Catalysing The Growth Of
An Innovation Driven Biotech Enterprise
About BIRAC
A ‘Not for Profit Company’ set up by Department of Biotechnology
(DBT), Government of India as an Interface Agency to strengthen
and empower the emerging Biotech enterprise to undertake
strategic research and innovation, addressing nationally relevant
product development needs.
BIRAC’s DNA
Vision
“To Stimulate, foster and enhance the strategic research and innovation capabilities of the Indian biotech industry,
particularly start ups and SME’s, for creation of affordable products addressing the needs of the largest section of
society.”
Mission
“Facilitate and mentor the generation and translation of innovative ideas into biotech products and services by the
industry, promote academia – industry collaboration, forge international linkages, encourage techno entrepreneurship
and enable creation and sustainability of viable bio enterprises.”
Foster innovation and entrepreneurship in all places of research
Promote affordable innovation in key social sectors
Higher focus on start ups & small and medium enterprises
Strategies
Contribute through partners for capability enhancement
Encourage diffusion of innovation through partners
Enable commercialization of discovery
Ensure global competitiveness of Indian enterprises
BIRAC Support to Biotech Ecosystem
BIG
Encourage Entrepreneurship; Grant up-to INR 50 Lakhs; Support to ~35 Entrepreneurs in 2 calls
Start-Ups/Registered Company with a functional Lab; Scientists/ Faculty/ Researchers associated with
bio-Incubators
SBIRI
Launched in 2005; early stage funding for high risk innovative research
Support for early stage, pre-proof-of-concept research in biotechnology by industry
Till date support extended to ~ 105 companies
BIPP
Government partnership with Industries for support on a cost sharing basis
Support for high risk, highly innovative accelerated technology development
Till date support extended to ~ 91 companies
CRS
Bridging Industry-Academia gap
Support to Academia for Validation and Translation
Industry acts as Validation Partner with IP rights with Academia
BIRAC Support to Biotech Ecosystem
BISS
Strengthening and up-grading existing Bio-Incubators and to establish new state-of-the-art facilities
Support to 12 existing Incubator facilities at New Delhi, Pune, Gujarat, Hyderabad, Kanpur, Bhubaneswar
and Chennai; ~70,000 sq. ft. of bio-incubator space created
New incubators at RCB, Faridabad and C-CAMP, Bangalore
Social Innovation Programme for Products Affordable & Relevant to Societal Health
SPARSH
Launched on 15th August 2013
Securing Maternal and Child Health; Achieving WHO’s MDG 4 & 5
GCI-I
BIRAC-DBT-Bill & Melinda Gates Foundation
Launched on 28th August 2013
Securing Family Health, Agriculture, Food & Nutrition
GCI-II
Reinvent the Toilet Challenge: India
Launched on 02nd October 2013
Focusing development of innovative sanitation technologies
Building Strategic Alliances
 BIRAC – DBT – Bill & Melinda Gates Foundation (BMGF) Partnership
• For collaborative scientific and technological research to alleviate some of the world’s most
critical health and development issues.
 Collaboration with Wellcome Trust, UK
• Focusing on translation research for safe, effective and affordable healthcare products
 Collaboration with CEFIPRA
• Emphasizing on technological interventions in red and green biotechnology
 Partnership with TEKES
• Aiming at promoting cross-border resource mobility for enhancing innovative competitiveness
and partnerships
Network and partner with like minded organisations to reach out to all its stakeholders and accomplish mission effectively
BIRAC’s
National Presence
Performance Snapshot – BIPP and SBIRI
Funding and Mentoring
• Support to 200 companies
• Funding support of ~ USD 225 Mn (100 Mn. GOI, 125 Mn. Company)
• Mentoring for ~275 innovative projects
Fund Flow Analysis
Promoting Collaborations
Assessing the Impact
New start-ups supported and scaled up
Small and medium enterprises strengthened
New technologies brought to market
Affordable products developed
IP Generated
Investments made on discovery and innovation research.
These will include high risk - high return and high risk – low
return but with high social impact.
50
150
11
15
23
1380 Cr.
Stepping-Up the Innovation Ladder
Market
Scale
Pilot
Validation
Prototype
Proof of
Concept
Idea
BIG
SBIRI
BIPP
CRS
BIRAC’s Areas of Support
Health Care
BioInformatics
Infrastructure
Agriculture
Industrial
Biotechnology
BIRAC’s Support to Nanotechnology
Idea to Proof of Concept
SNO
Title Of the proposal
Relevant Area
Salient Features
1
Testing the feasibility of Nano
magnetic disc based ablation of
Cancer cells in vitro
Healthcare
Applies nanotechnology in a
non-surgical targeted cancer
cell removal procedure that
eliminates the risks and
limitations of surgical and
non-surgical procedures
2
Engineered stable, nano-sized
bubble liposomes - a commercially
viable drug delivery platform
Healthcare
A novel & viable drug
delivery platform of drugfilled bubble liposomes
3
Production of collagen and byproducts from fresh water fish
origin for biomedical applications
Healthcare
Collagen from fresh water
fish origin to offer higher
thermal stability similar to
mammalian origin for various
biomedical products
Idea to Proof of Concept -contd
SNO
Title Of the proposal
Relevant Area
Salient Features
4
Design and Development of a Rapid
Point-of-Care Device for Endotoxin
Detection in Critically Ill/Septicemia
Patients
Healthcare
An affordable and robust laboratory scale
dot blot bioassay that uses
biofunctionalized gold nanoparticles as
reporter molecules for the efficient and
rapid detection of endotoxin in whole
serum
5
Detection of Circulating Tumor Cells
by Multifunctional Highly Dispersible
Polymeric-Magneto-Antibody
Nanosystem
Healthcare
The Polymeric-Magneto-Antibody
Nanosystem (PMAN) will reliably capture
the cancer cells from the artificial
Circulating Tumor Cell (CTC) blood samples
6
Biomimetic Bone Substitutes:
A proof of concept prototype for
synthetic bone substitute consisting
of a nano composite of Demineralised
matrix and
hydroxyapatite.
Healthcare
Provides the body’s own natural bone
growth factors to supplement the action of
the bone graft.
Idea to Proto Type
SNO
Title Of the proposal
1
Development and
characterization of lipid
carrier based nanogel
formulation for 5-Fluorouracil
2
Nanotechnology based
delivery of peptide inhibitors
for the treatment of
Osteoporosis
Relevant Area
Health Care
Health Care
Salient Features
Selectively localize the drug
to tumor tissues without
concurrent increase in its level
in healthy tissues
Peptide inhibitors are
expected to offer fewer side
effects as they prevent
interaction between specific
proteins
Proof of Concept to Scale UP
SNO
Title Of the proposal
Relevant Area
Salient Features
1
Production of poly-( Iactide-coglycolide) (pLG) nanoparticles
encapsulating antitubercular drugs
(rifampicin, isoniazid and
pyrazinamide(PLGA-NP-ATDs) in GMP
facilities
Health Care
Offers new regimens for
tuberculosis that could be
administered for a shorter
duration/more
intermittently without
sacrificing efficacy.
2
Evaluation of Platinum nanoparticles
for the treatment of Hormone
refractory prostate cancer
Health Care
Indigenous, cost effective
and affordable Platinum
based treatment for the
management of
malignancies
Proof of Concept to Scale UP –ContdSNO
Title Of the proposal
Relevant Area
Salient Features
3
Inorganic and polymer nanocomposites for micronutrient &
pesticide delivery: Boosting crop health
and yield
Agriculture
Nanotechnology based
delivery vehicles to supply
micro-nutrients &
pesticides to crops to boost
crop health, quality and
yield
4
Commercial Scale Production of Nano
pesticides for Indian Agro-industry
Agriculture
Being physical action
insecticide, the product is
better than neuro toxic
products presently in use.
Environmentally safer and
gives prolonged control of
the insect pests
Challenges in Taking the Nanotechnology related Projects Forward
Accessibility To Government approved labs for doing nanomaterial risk assessment
Absence of clear cut regulatory guidelines necessary for commercialization
Absence of International collaboration for better technology access especially for safety
compliance
Next Steps
Funding Agencies to consider setting of Labs for Risk Assesment
Authorized People to immediately look into defining regulatory guidelines for
nanotechnology product
Funding bodies to consider Transfer of Technology for nanotechnology interventions relevant
to India
Thank you